GlassScriptPhysician profile
Daniel Minh Le
NPI 1295244325
$6,476.58
in general payments reported to CMS, 2019-2025
18 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $454 · 2022: $874 · 2023: $1,493 · 2024: $2,481 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,649 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,648.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $1,837.96 | 2022-2025 | Omnipod, Omnipod |
| Lilly USA, LLC | $1,461.08 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $593.40 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $579.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $572.86 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.04 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $347.23 | 2021-2024 | Farxiga |
| Xeris Pharmaceuticals, INC. | $135.32 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Amphastar Pharmaceuticals, INC. | $105.32 | 2024-2025 | |
| Cequr Corporation | $84.53 | 2022-2024 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $66.57 | 2022-2024 | |
| Glaxosmithkline, LLC. | $56.00 | 2025 | Nucala |
| Ibsa Pharma INC. | $17.75 | 2023 | Tirosint, Licart |
| Becton, Dickinson and Company | $15.64 | 2022 | |
| Mannkind Corporation | $15.56 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $14.87 | 2023 | Inpen Smart Insulin Delivery System |
| Halozyme INC | $14.56 | 2023 | |
| Antares Pharma, INC. | $13.01 | 2023 | Nocdurna, Tlando, Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.